Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, today announced that Anthem Blue Cross Blue Shield (BCBS) has issued a positive coverage policy for endobronchial valves, including Pulmonx’s Zephyr® Valve, for severe emphysema, a form of COPD. This follows similar coverage decisions by other BCBS plans and brings the total BCBS covered members in the US to 59 million.
August 20, 2021
· 5 min read